Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 241 of the 244 references it cites were found in a registry or an index.

Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles

Open access
Kalkman, Hans O. · 2023 · Biomedicines

Abstract

Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process, allowing proposals how to accelerate the discovery process. Risk factors for depression initiate an infection-like inflammation in the brain that involves activation microglial Toll-like receptors and glycogen synthase kinase-3β (GSK3β). GSK3β activity alters the balance between two competing transcription factors, the pro-inflammatory/pro-oxidative transcription factor NFκB and the neuroprotective, anti-inflammatory and anti-oxidative transcription factor NRF2. The antidepressant activity of tricyclic antidepressants is assumed to involve activation of GS-coupled microglial receptors, raising intracellular cAMP levels and activation of protein kinase A (PKA). PKA and similar kinases inhibit the enzyme activity of GSK3β. Experimental antidepressant principles, including cannabinoid receptor-2 activation, opioid μ receptor agonists, 5HT2 agonists, valproate, ketamine and electrical stimulation of the Vagus nerve, all activate microglial pathways that result in GSK3β-inhibition. An in vitro screen for NRF2-activation in microglial cells with TLR-activated GSK3β activity, might therefore lead to the detection of totally novel antidepressant principles with, hopefully, an improved therapeutic efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines11030806

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of the process by which risk factors for depression increase inflammatory and pro-oxidative processes in the brain and lead to physical and psychological symptoms of depressive disorder. Depression risk factors activate Toll-like receptor-4 (TLR4) on microglia cells, which causes activation of the kinase GSK3β and an increase in gene transcription by NFκB (p65/RelA). Antidepressant compounds, via activation of different members of the AGC protein-kinase family, including protein kinase A (PKA), PKB/Akt, and PKC, inhibit the enzyme activity of GSK3β. This, on the one hand, inhibits NFκB-signaling and, on the other hand, increases gene transcription by CREB and NRF2, two transcription factors that promote the transcription of neuroprotective, anti-inflammatory, and anti-oxidant proteins. This way, antidepressants neutralize the negative effects evoked by TLR4 activation. CREB: cyclic-AMP responsive element binding protein; NRF2: nuclear factor erythroid 2-related factor 2. The transcription factors are enclosed in an ellipse. For further details, the reader is referred to the text.
Figure 1 Schematic representation of the process by which risk factors for depression increase inflammatory and pro-oxidative processes in the brain and lead to physical and psychological symptoms of depressive disorder. Depression risk factors activate Toll-like receptor-4 (TLR4) on microglia cells, which causes activation of the kinase GSK3β and an increase in gene transcription by NFκB (p65/RelA). Antidepressant compounds, via activation of different members of the AGC protein-kinase family, including protein kinase A (PKA), PKB/Akt, and PKC, inhibit the enzyme activity of GSK3β. This, on the one hand, inhibits NFκB-signaling and, on the other hand, increases gene transcription by CREB and NRF2, two transcription factors that promote the transcription of neuroprotective, anti-inflammatory, and anti-oxidant proteins. This way, antidepressants neutralize the negative effects evoked by TLR4 activation. CREB: cyclic-AMP responsive element binding protein; NRF2: nuclear factor erythroid 2-related factor 2. The transcription factors are enclosed in an ellipse. For further details, the reader is referred to the text.CC BY · PubMed Central
Figure 2 Dopamine (DA) and serotonin (5HT) activate distinct receptor subtypes and signaling pathways in microglia and neurons. In microglial cells, the functional outcome is an inhibition of GSK3β, whereas activation of the D2-receptor in neurons results in activation of GSK3β. Whether activation of the 5HT2A receptor in neurons leads to GSK3β activation has not been investigated.
Figure 2 Dopamine (DA) and serotonin (5HT) activate distinct receptor subtypes and signaling pathways in microglia and neurons. In microglial cells, the functional outcome is an inhibition of GSK3β, whereas activation of the D2-receptor in neurons results in activation of GSK3β. Whether activation of the 5HT2A receptor in neurons leads to GSK3β activation has not been investigated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 244 references

Cited by

See all 18

Metadata

Authors
Kalkman, H. O.
Affiliations
University of Zurich (CH)
Corresponding author
Kalkman, Hans O.
Venue
Biomedicines
Publisher
MDPI AG
Published
2023-03-07
Volume
11
Issue
3
Pages
806
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4323361230
Cited by
18
References
244
Citations by year
2026: 5 · 2025: 1 · 2024: 6 · 2023: 6
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
depression, antidepressants, microglia, glycogen synthase kinase-3β, GSK-3β inhibition, Toll-like receptors, neuroinflammation, NF-κB, Nrf2, protein kinase A, cAMP signaling, tricyclic antidepressants, CB2 receptor, valproic acid, ketamine, vagus nerve stimulation, in vitro screening

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles. https://app.cochat.ai/papers/10.3390/biomedicines11030806
The paper
Kalkman, H. O. (2023). Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles. Biomedicines. https://doi.org/10.3390/biomedicines11030806

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.